ClinicalTrials.gg
RecruitingNCT07310472Updated Jan 22, 2026

Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility

An interventional study of Possibility to get live attenuated nasal influenza vaccine at daycare in Influenza Vaccination, sponsored by Turku University Hospital. Recruiting at 1 site in Finland. Open to participants aged 2 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Turku University Hospital · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,000
Allocation
Randomized
Ages
2 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Influenza, Human with a site in Finland — 3 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Finland.

Planned enrollment
10th of 37
6,000 · median 807
Started
2025
with 1 other
No phase
2 of 43
1 open now
Registered
43rd of 43
by date
Lead sponsor
2 of 43
Turku University Hospital

Among the 43 studies in Influenza, Human with a site in Finland, this one is the 10th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 with no phase, and was the 43rd registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 43 studies in Influenza, Human with a site in Finland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 2 Years to 6 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Influenza, Human with a site in Finland, or all of them as a file.
02

Study summary

The goal of this intervention study is to learn if giving children influenza vaccinations in early childhood education facilities (i.e., daycare) will increase vaccination coverage compared to giving vaccinations only at healthcare. The main question it aims to answer is:

  • Does offering children nasal influenza vaccine in daycare result in higher proportion of children getting influenza vaccine.

Researchers will compare daycare setting and healthcare setting as the location of giving influenza vaccines to children to see if more children will get vaccinated if they have an opportunity to receive nasal influenza vaccine at daycare.

Participants in the intervention group will:

  • Have the opportunity to receive influenza vaccine in the daycare or in the healthcare

Participants in the comparison group will:

  • Have the opportunity to receive influenza vaccine in the healthcare only
03

Conditions studied

  • Influenza Vaccination

Browse trials for

Keywords

  • Influenza
  • Children
  • Vaccination coverage
  • Nasal influenza vaccine
04

Who can participate

Ages eligible
2 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Attending early childhood education (daycare) in the city of Turku

Exclusion criteria

Exclusion Criteria:

  • No exclusion criteria
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6,000 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Participants are offered a nasal influenza vaccine at daycare

    Behavioral: Possibility to get live attenuated nasal influenza vaccine at daycare

  • No intervention
    Comparison group

    Participants are not offered a nasal influenza vaccine at daycare

Interventions

  • BehavioralPossibility to get live attenuated nasal influenza vaccine at daycare

    The intervention is the possibility to get influenza vaccine in the daycare, in comparison to routine practice of getting influenza vaccine in a healthcare setting.

06

What researchers measure

Primary outcomes

  1. Influenza vaccination coverage

    Study child receiving any influenza vaccine

    Time frame: From enrollment to the end of seasonal influenza vaccinations about 3 to 10 weeks later.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — According to national regulations, it is not allowed to share individual health data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2026, 5 months after the start.

Of 147 non-industry interventional studies with no phase under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 5 months is below that.

Counting every sponsor, half of 167 studies reached it within 6 months; a quarter within 3 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Oct 27, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07310472
Collaborators
University of Turku
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Oct 27, 2025
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Jan 22, 2026

Study contacts

Ville Peltola, MD, PhD
Contact
ville.peltola@varha.fi
+35823132415

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion